Champions Oncology (CSBR) Other Non-Current Liabilities (2011 - 2026)
Champions Oncology's (CSBR) quarterly Other Non-Current Liabilities came in at $215000.0 in Q3 2026, up 225.76% year-over-year from $66000.0 in Q3 2025, and up 2971.43% on a QoQ basis from $7000.0 in Q2 2026.
Powered by 
Analysis
Champions Oncology (CSBR) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Champions Oncology (CSBR) has 16 years of Other Non-Current Liabilities data on file, last reported at $215000.0 in Q3 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 225.76% year-over-year to $215000.0 in Q3 2026; TTM through Jul 2026 was $215000.0, a 225.76% increase from a year earlier, with the FY2026 full-year figure at $7000.0, down 91.76% from the prior year.
- Other Non-Current Liabilities for Q3 2026 stood at $215000.0, up from $7000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $660000.0 in Q3 2022 and bottomed at $7000.0 in Q2 2026.
- Historically, Other Non-Current Liabilities has averaged $331210.5 across 5 years, with a median of $363000.0 in 2024.
- The largest YoY upside for Other Non-Current Liabilities was 225.76% in 2026 against a maximum downside of 91.76% in 2026.
- Year by year, Other Non-Current Liabilities stood at $624000.0 in 2022, then slipped by 23.72% to $476000.0 in 2023, then tumbled by 31.93% to $324000.0 in 2024, then tumbled by 85.8% to $46000.0 in 2025, then soared by 367.39% to $215000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $215000.0 in Q3 2026, $7000.0 in Q2 2026, and $27000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 215,000.00 |
| Apr 30, 2026 | 7,000.00 |
| Jan 31, 2026 | 27,000.00 |
| Oct 31, 2025 | 46,000.00 |
| Jul 31, 2025 | 66,000.00 |
| Apr 30, 2025 | 85,000.00 |
| Jan 31, 2025 | 285,000.00 |
| Oct 31, 2024 | 324,000.00 |
| Jul 31, 2024 | 363,000.00 |
| Apr 30, 2024 | 401,000.00 |
| Jan 31, 2024 | 439,000.00 |
| Oct 31, 2023 | 476,000.00 |
| Jul 31, 2023 | 514,000.00 |
| Apr 30, 2023 | 551,000.00 |
| Jan 31, 2023 | 588,000.00 |
| Oct 31, 2022 | 624,000.00 |
| Jul 31, 2022 | 660,000.00 |
| Apr 30, 2022 | 391,000.00 |
| Jan 31, 2022 | 231,000.00 |
| Oct 31, 2021 | 235,000.00 |